86 related articles for article (PubMed ID: 9575420)
1. Anti-neoplastic properties of human corticotropin releasing factor: involvement of the nitric oxide pathway.
Tjuvajev J; Kolesnikov Y; Joshi R; Sherinski J; Koutcher L; Zhou Y; Matei C; Koutcher J; Kreek MJ; Blasberg R
In Vivo; 1998; 12(1):1-10. PubMed ID: 9575420
[TBL] [Abstract][Full Text] [Related]
2. Corticotropin-releasing factor decreases vasogenic brain edema.
Tjuvajev J; Uehara H; Desai R; Beattie B; Matei C; Zhou Y; Kreek MJ; Koutcher J; Blasberg R
Cancer Res; 1996 Mar; 56(6):1352-60. PubMed ID: 8640825
[TBL] [Abstract][Full Text] [Related]
3. Cell-type specific calcium signaling by corticotropin-releasing factor type 1 (CRF1) and 2a (CRF2(a)) receptors: phospholipase C-mediated responses in human embryonic kidney 293 but not SK-N-MC neuroblastoma cells.
Dautzenberg FM; Gutknecht E; Van der Linden I; Olivares-Reyes JA; Dürrenberger F; Hauger RL
Biochem Pharmacol; 2004 Nov; 68(9):1833-44. PubMed ID: 15450949
[TBL] [Abstract][Full Text] [Related]
4. Signaling properties of mouse and human corticotropin-releasing factor (CRF) receptors: decreased coupling efficiency of human type II CRF receptor.
Xiong Y; Xie LY; Abou-Samra AB
Endocrinology; 1995 May; 136(5):1828-34. PubMed ID: 7720627
[TBL] [Abstract][Full Text] [Related]
5. Effects of nitric oxide on proliferation and differentiation of rat brown adipocytes in primary cultures.
Nisoli E; Clementi E; Tonello C; Sciorati C; Briscini L; Carruba MO
Br J Pharmacol; 1998 Oct; 125(4):888-94. PubMed ID: 9831929
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of mouse melanoma cell proliferation by corticotropin-releasing hormone and its analogs.
Carlson KW; Nawy SS; Wei ET; Sadée W; Filov VA; Rezsova VV; Slominski A; Quillan JM
Anticancer Res; 2001; 21(2A):1173-9. PubMed ID: 11396159
[TBL] [Abstract][Full Text] [Related]
7. Endothelium-dependent and -independent mechanisms of vasorelaxation by corticotropin-releasing factor in pregnant rat uterine artery.
Jain V; Vedernikov YP; Saade GR; Chwalisz K; Garfield RE
J Pharmacol Exp Ther; 1999 Feb; 288(2):407-13. PubMed ID: 9918539
[TBL] [Abstract][Full Text] [Related]
8. Quantification and morphologic demonstration of reactive oxygen species produced by Walker 256 tumor cells in vitro and during metastasis in vivo.
Soares FA; Shaughnessy SG; MacLarkey WR; Orr FW
Lab Invest; 1994 Oct; 71(4):480-9. PubMed ID: 7967504
[TBL] [Abstract][Full Text] [Related]
9. Constrained corticotropin-releasing factor antagonists with i-(i + 3) Glu-Lys bridges.
Miranda A; Lahrichi SL; Gulyas J; Koerber SC; Craig AG; Corrigan A; Rivier C; Vale W; Rivier J
J Med Chem; 1997 Oct; 40(22):3651-8. PubMed ID: 9357532
[TBL] [Abstract][Full Text] [Related]
10. Urocortin-induced relaxation in the human internal mammary artery.
Chen ZW; Huang Y; Yang Q; Li X; Wei W; He GW
Cardiovasc Res; 2005 Mar; 65(4):913-20. PubMed ID: 15721872
[TBL] [Abstract][Full Text] [Related]
11. Nitric oxide mediates the mitogenic effects of insulin and vascular endothelial growth factor but not of leptin in endothelial cells.
Józkowicz A; Pankiewicz J; Dulak J; Partyka L; Wybrańska I; Huk I; Dembińska-Kieć A
Acta Biochim Pol; 1999; 46(3):703-15. PubMed ID: 10698278
[TBL] [Abstract][Full Text] [Related]
12. eNOS, nNOS, cGMP and protein kinase G mediate the inhibitory effect of pancreastatin, a chromogranin A-derived peptide, on growth and proliferation of hepatoma cells.
Díaz-Troya S; Najib S; Sánchez-Margalet V
Regul Pept; 2005 Feb; 125(1-3):41-6. PubMed ID: 15582712
[TBL] [Abstract][Full Text] [Related]
13. Stimulating effect of HIV-1 coat protein gp120 on corticotropin-releasing hormone and arginine vasopressin in the rat hypothalamus: involvement of nitric oxide.
Costa A; Nappi RE; Polatti F; Poma A; Grossman AB; Nappi G
Exp Neurol; 2000 Dec; 166(2):376-84. PubMed ID: 11085902
[TBL] [Abstract][Full Text] [Related]
14. Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF(1)) receptors: identification of amino acids mediating high-affinity astressin binding and functional antagonism.
Dautzenberg FM; Wille S
Regul Pept; 2004 May; 118(3):165-73. PubMed ID: 15003833
[TBL] [Abstract][Full Text] [Related]
15. Constrained corticotropin-releasing factor (CRF) agonists and antagonists with i-(i+3) Glu-Xaa-DXbb-Lys bridges.
Koerber SC; Gulyas J; Lahrichi SL; Corrigan A; Craig AG; Rivier C; Vale W; Rivier J
J Med Chem; 1998 Dec; 41(25):5002-11. PubMed ID: 9836618
[TBL] [Abstract][Full Text] [Related]
16. The phenotypic differentiation of locus ceruleus noradrenergic neurons mediated by brain-derived neurotrophic factor is enhanced by corticotropin releasing factor through the activation of a cAMP-dependent signaling pathway.
Traver S; Marien M; Martin E; Hirsch EC; Michel PP
Mol Pharmacol; 2006 Jul; 70(1):30-40. PubMed ID: 16569708
[TBL] [Abstract][Full Text] [Related]
17. Endothelial cell damage by Walker carcinosarcoma cells is dependent on vitronectin receptor-mediated tumor cell adhesion.
Shaughnessy SG; Lafrenie RM; Buchanan MR; Podor TJ; Orr FW
Am J Pathol; 1991 Jun; 138(6):1535-43. PubMed ID: 1711295
[TBL] [Abstract][Full Text] [Related]
18. [Study on the relationship between cadmium immunotoxicity and corticotropin-releasing factor].
Zhang X; Li D; Dong S; Zhang J
Wei Sheng Yan Jiu; 2000 Jul; 29(4):193-6. PubMed ID: 12520913
[TBL] [Abstract][Full Text] [Related]
19. Nitroglycerin enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via nitric oxide pathway.
Huang L; Qiu N; Zhang C; Wei HY; Li YL; Zhou HH; Xiao ZS
Acta Pharmacol Sin; 2008 May; 29(5):580-6. PubMed ID: 18430366
[TBL] [Abstract][Full Text] [Related]
20. Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: evidence for evolutionary differences.
Dautzenberg FM; Py-Lang G; Higelin J; Fischer C; Wright MB; Huber G
J Pharmacol Exp Ther; 2001 Jan; 296(1):113-20. PubMed ID: 11123370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
